Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy

References

• Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2019 national survey on drug use and health. U.S. Department of Health and Human Services. 2020; :1–114.
   Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. AJP. 2006;163(11):1905–1917.
   Web of Science ®Google Scholar
• Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic 2019. [cited 2021 June 14]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
   Google Scholar
• Parikh RM, Lebowitz BD. Current perspectives in the management of treatment-resistant depression. Dialogues Clin Neurosci. 2004;6(1):53–60.
   PubMedGoogle Scholar
• Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234.
   PubMed Web of Science ®Google Scholar
• Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J Clin Psychiatry. 2018;79(2):17m11725.
   PubMed Web of Science ®Google Scholar
• Pilon D, Joshi K, Sheehan JJ, et al. Burden of treatment-resistant depression in Medicare: a retrospective claims database analysis. PLoS One. 2019;14(10):e0223255.
   PubMed Web of Science ®Google Scholar
• Pilon D, Sheehan JJ, Szukis H, et al. Medicaid spending burden among beneficiaries with treatment-resistant depression. J Comp Eff Res. 2019;8(6):381–392.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):126–135.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder: 3rd edition 2010. [September 18, 2019]. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
   Google Scholar
• Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661.
   PubMed Web of Science ®Google Scholar
• Keyloun KR, Hansen RN, Hepp Z, et al. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD). CNS Drugs. 2017;31(5):421–432.
   PubMed Web of Science ®Google Scholar
• Citrome L, Johnston S, Nadkarni A, et al. Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and Medicaid insured patients newly initiating atypical antipsychotics. Curr Drug Saf. 2014;9(3):227–235.
   PubMedGoogle Scholar
• Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9(5–6):41–46.
   PubMedGoogle Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.
   PubMed Web of Science ®Google Scholar
• Wu B, Cai Q, Sheehan JJ, et al. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression. PLoS One. 2019;141(8):e0220763.
   Google Scholar
• Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ), Non-Geriatric Population, version 2. 2015.
   Google Scholar
• Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ), Geriatric Population, version 3. 2016.
   Google Scholar
• Zhdanava M, Karkare S, Pilon D, et al. Prevalence of pre-existing conditions relevant for adverse events and potential drug-drug interactions associated with augmentation therapies among patients with treatment-resistant depression. Adv Ther. 2021;38(9):4900–4916.
   PubMed Web of Science ®Google Scholar
• Adhikari K, Patten SB, Lee S, et al. Adherence to and persistence with antidepressant medication during pregnancy: does it differ by the class of antidepressant medication prescribed? Can J Psychiatry. 2019;64(3):199–208.
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Saragoussi D, Despiegel N, et al. The 6-month persistence on SSRIs and associated economic burden. J Med Econ. 2010;13(3):527–536.
   PubMedGoogle Scholar
• Kim-Romo DN, Rascati KL, Richards KM, et al. Medication adherence and persistence in patients with severe major depressive disorder with psychotic features: antidepressant and second-generation antipsychotic therapy versus antidepressant monotherapy. J Manag Care Spec Pharm. 2016;22(5):588–596.
   PubMed Web of Science ®Google Scholar
• Solem CT, Shelbaya A, Wan Y, et al. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. Neuropsychiatr Dis Treat. 2016;12:2755–2764.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210.
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101–108.
   PubMed Web of Science ®Google Scholar
• Zhdanava M, Kuvadia H, Joshi K, et al. Economic burden of treatment-resistant depression in privately insured U.S. patients with physical conditions. JMCP. 2020;26(8):996–1007.
   PubMed Web of Science ®Google Scholar
• Culpepper L. Managing depression and medical comorbidities. Postgrad Med. 2003;114(5 Suppl Treating):26–38.
   PubMedGoogle Scholar
• Roca M, Armengol S, García-García M, et al (editors). Adherence to antidepressant treatment in depressive patients with comorbid psychiatric disorders. 19th European Congress of Psychiatry; 2011. European Psychiatry.
   Google Scholar
• Han B, Olfson M, Mojtabai R. Depression care among depressed adults with and without comorbid substance use disorders in the United States. Depress Anxiety. 2017;34(3):291–300.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69(6):946–958.
   PubMed Web of Science ®Google Scholar
• Solmi M, Miola A, Croatto G, et al. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry. 2021;43(2):189–202.
   Google Scholar
• Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165(21):2497–2503.
   PubMedGoogle Scholar